“Doll #135 with vitiligo”: Are alopecia and vitiligo Barbie worth the hype?

Toy manufacturer Mattel released a new line of diverse Barbie dolls earlier this year, including dolls with alopecia and vitiligo. The new dolls have been widely celebrated, with both media and dermatologists proposing that the dolls could provide significant benefits for the low self-esteem and societal exclusion suffered by children with similar dermatoses. However, the reality may be very different. Here, we present existing research on the impact of diverse dolls on children’s play and psychology to argue that the dolls’ proposed benefits for children with alopecia and vitiligo are unlikely to materialize; rather, alopecia and vitiligo Barbie could prove more harmful than beneficial.     

Longitudinal Positron Emission Tomography of Dopamine Synthesis in Subjects with GBA1 Mutations

Mutations in GBA1, the gene mutated in Gaucher disease, are a common genetic risk factor for Parkinson disease, although the penetrance is low. We performed [¹⁸F]-fluorodopa positron emission tomography studies of 57 homozygous and heterozygous GBA1 mutation carriers (15 with parkinsonism) and 98 controls looking for early indications of dopamine loss using voxelwise analyses to identify group differences in striatal [¹⁸F]-fluorodopa uptake (K_i). Forty-eight subjects were followed longitudinally. Cross-sectional and longitudinal comparisons of K_i and K_i change found significant effects of Parkinson disease. However, at baseline and over time, striatal [¹⁸F]-fluorodopa uptake in mutation carriers without parkinsonism did not significantly differ from controls. ANN NEUROL 2020;87:652–657     

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum

Expanding use of immune-checkpoint inhibitors (ICIs) underscores the importance of accurate diagnosis and timely management of neurological immune-related adverse events (irAE-N). We evaluate the real-world frequency, phenotypes, co-occurring immune-related adverse events (irAEs), and long-term outcomes of severe, grade III to V irAE-N at a tertiary care center over 6 years. We analyze how our experience supports published literature and professional society guidelines. We also discuss these data with regard to common clinical scenarios, such as combination therapy, ICI rechallenge and risk of relapse of irAE-N, and corticosteroid taper, which are not specifically addressed by current guidelines and/or have limited data. Recommendations for management and future irAE-N reporting are outlined. ANN NEUROL 2020;87:659–669